Sentynl Therapeutics, a Zydus Group company announces global acquisition of Zokinvy
Zokinvy is approved in the US, European Union and Great Britain, and Japan for the treatment of Progeria, a collection of ultra-rare, fatal, genetic premature aging diseases that accelerate mortality in young patients